Hospira Drug Patent Portfolio
Hospira owns 3 orange book drugs protected by 20 US patents Given below is the list of Hospira's drug patents along with their expiration dates.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10357535 | Daptomycin formulations and uses thereof | 11 Sep, 2033 | Active |
| US9655946 | Daptomycin formulations and uses thereof | 11 Sep, 2033 | Active |
| US9717852 | Cartridge holder and pen-type injector | 08 Apr, 2033 | Active |
| US8242158 | Dexmedetomidine premix formulation | 04 Jul, 2032 | Active |
| US8338470 | Dexmedetomidine premix formulation | 04 Jul, 2032 | Active |
| US8455527 | Methods of treatment using a dexmedetomidine premix formulation | 04 Jul, 2032 | Active |
| US8648106 | Dexmedetomidine premix formulation | 04 Jul, 2032 | Active |
| US9320712 | Dexmedetomidine premix formulation | 04 Jul, 2032 | Active |
| US9616049 | Dexmedetomidine premix formulation | 04 Jul, 2032 | Active |
| US10016396 | Dexmedetomidine premix formulation | 04 Jan, 2032 | Active |
| US8242158 | Dexmedetomidine premix formulation | 04 Jan, 2032 | Active |
| US8338470 | Dexmedetomidine premix formulation | 04 Jan, 2032 | Active |
| US8455527 | Methods of treatment using a dexmedetomidine premix formulation | 04 Jan, 2032 | Active |
| US8648106 | Dexmedetomidine premix formulation | 04 Jan, 2032 | Active |
| US9320712 | Dexmedetomidine premix formulation | 04 Jan, 2032 | Active |
| US9616049 | Dexmedetomidine premix formulation | 04 Jan, 2032 | Active |
| US6716867 | Use of dexmedetomidine for ICU sedation | 01 Oct, 2019 | Expired |
| US6716867 | Use of dexmedetomidine for ICU sedation | 31 Mar, 2019 | Expired |
| US4910214 | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist | 15 Jan, 2014 | Expired |
| US4910214 | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist | 15 Jul, 2013 | Expired |
Latest Legal Activities on Hospira's Drug Patents
Given below is the list of recent legal activities going on the following drug patents of Hospira.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Payment of Maintenance Fee, 12th Year, Large Entity | 10 May, 2024 | US8338470 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 11 Jan, 2024 | US8242158 |
|
Email Notification
Critical
| 20 Sep, 2023 | US11759497 |
|
Recordation of Patent Grant Mailed
Critical
| 19 Sep, 2023 | US11759497 |
| Mail Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
|
Patent Issue Date Used in PTA Calculation
Critical
| 19 Sep, 2023 | US11759497 |
| Recordation of Patent eGrant | 19 Sep, 2023 | US11759497 |
| Patent eGrant Notification | 19 Sep, 2023 | US11759497 |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Sep, 2023 | US9320712 |
|
Email Notification
Critical
| 01 Sep, 2023 | US11759497 |
|
Issue Notification Mailed
Critical
| 30 Aug, 2023 | US11759497 |
| Dispatch to FDC | 09 Aug, 2023 | US11759497 |
|
Application Is Considered Ready for Issue
Critical
| 09 Aug, 2023 | US11759497 |
|
Issue Fee Payment Verified
Critical
| 08 Aug, 2023 | US11759497 |
|
Issue Fee Payment Received
Critical
| 08 Aug, 2023 | US11759497 |
Hospira's Drug Patent Litigations
Hospira's drugs have been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Aug 11, 2016, against patent number US8648106. The petitioner Amneal Pharmaceuticals LLC, challenged the validity of this patent, with Hospira, Inc. as the respondent. Click below to track the latest information on how companies are challenging Hospira's patents.
| Patent | Proceeding Filing Date | Status | Respondent | Petitioner |
|---|---|---|---|---|
 | ||||
| US8242158 | March, 2017 |
Terminated-Denied
(06 Sep, 2017)
| Hospira, Inc. | Fresenius Kabi USA, LLC |
| US8338470 | March, 2017 |
Terminated-Denied
(06 Sep, 2017)
| Hospira, Inc. | Fresenius Kabi USA, LLC |
| US8455527 | March, 2017 |
Terminated-Denied
(06 Sep, 2017)
| Hospira, Inc. | Fresenius Kabi USA, LLC |
| US8338470 | August, 2016 |
Terminated-Settled
(26 May, 2017)
| Hospira, Inc. | Amneal Pharmaceuticals LLC |
| US8242158 | August, 2016 |
Terminated-Settled
(19 May, 2017)
| Hospira, Inc. | Amneal Pharmaceuticals LLC |
| US8455527 | August, 2016 |
Terminated-Settled
(19 May, 2017)
| Hospira, Inc. | Amneal Pharmaceuticals LLC |
| US8648106 | August, 2016 |
Terminated-Denied
(03 Feb, 2017)
| Hospira, Inc. | Amneal Pharmaceuticals LLC |
Hospira Drug Patents' Oppositions Filed in EPO
Hospira drug patents have faced multiple oppositions in the European Patent Office. The earliest opposition was filed on Jan 09, 2019, by Fresenius Kabi Deutschland Gmbh. This opposition was filed on patent number EP12823234A. Click below to reveal the latest opposition data.
| Application | Filing Date | Opposition Party | Legal Status |
|---|---|---|---|
| | |||
| EP12823234A | Jan, 2019 | Fresenius Kabi Deutschland GmbH | Revoked |
Hospira's Family Patents
Hospira Drug List
Given below is the complete list of Hospira's drugs and the patents protecting them.
1. Daptomycin
Daptomycin is protected by 2 patents, out of which none have expired yet. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US10357535 | Daptomycin formulations and uses thereof |
11 Sep, 2033
(8 years from now)
| Active |
| US9655946 | Daptomycin formulations and uses thereof |
11 Sep, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Daptomycin's drug page
2. Liposyn Iii 30%
Liposyn Iii 30% is protected by 1 patent, which is still active. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US9717852 | Cartridge holder and pen-type injector |
08 Apr, 2033
(8 years from now)
| Active |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Liposyn Iii 30%'s drug page
3. Precedex
Precedex is protected by 17 patents, out of which 4 have expired. Check out its patent list below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| US8242158
(Pediatric)
| Dexmedetomidine premix formulation |
04 Jul, 2032
(7 years from now)
| Active |
| US8338470
(Pediatric)
| Dexmedetomidine premix formulation |
04 Jul, 2032
(7 years from now)
| Active |
| US8455527
(Pediatric)
| Methods of treatment using a dexmedetomidine premix formulation |
04 Jul, 2032
(7 years from now)
| Active |
| US8648106
(Pediatric)
| Dexmedetomidine premix formulation |
04 Jul, 2032
(7 years from now)
| Active |
| US9320712
(Pediatric)
| Dexmedetomidine premix formulation |
04 Jul, 2032
(7 years from now)
| Active |
| US9616049
(Pediatric)
| Dexmedetomidine premix formulation |
04 Jul, 2032
(7 years from now)
| Active |
| US10016396 | Dexmedetomidine premix formulation |
04 Jan, 2032
(7 years from now)
| Active |
| US8242158 | Dexmedetomidine premix formulation |
04 Jan, 2032
(7 years from now)
| Active |
| US8338470 | Dexmedetomidine premix formulation |
04 Jan, 2032
(7 years from now)
| Active |
| US8455527 | Methods of treatment using a dexmedetomidine premix formulation |
04 Jan, 2032
(7 years from now)
| Active |
| US8648106 | Dexmedetomidine premix formulation |
04 Jan, 2032
(7 years from now)
| Active |
| US9320712 | Dexmedetomidine premix formulation |
04 Jan, 2032
(7 years from now)
| Active |
| US9616049 | Dexmedetomidine premix formulation |
04 Jan, 2032
(7 years from now)
| Active |
| US6716867
(Pediatric)
| Use of dexmedetomidine for ICU sedation |
01 Oct, 2019
(5 years ago)
| Expired |
| US6716867 | Use of dexmedetomidine for ICU sedation |
31 Mar, 2019
(5 years ago)
| Expired |
| US4910214
(Pediatric)
| Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
15 Jan, 2014
(10 years ago)
| Expired |
| US4910214 | Optical isomer of an imidazole derivative medetomidine as an alpha-2-receptor agonist |
15 Jul, 2013
(11 years ago)
| Expired |
Discover which of these patents contain the active ingredient(API) of the drug, their family patents, along with litigation and legal activity details of these patents on Precedex's drug page